Bernie Sanders keeps the heat on Novo’s high prices
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Category: Pharma
STAT+: Pharmalittle: We’re reading about pharma patent maneuvers, the U.S. warning J&J, and more
Hello, everyone, and how are you today? We are muddling along, but the middle of…
FDA formalizes protocol for international cancer trials
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about an Express Scripts lawsuit against FTC, AMR deaths, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: 11 people shaping psychedelics drug development
The field of psychedelics, once relegated to the fringes of science and medicine, is in…
STAT+: What pharma companies and insurers think about Medicare’s plan to cover digital treatments
In July, Medicare proposed to start paying for some mental health apps, in a move…
The news from ESMO: An immunotherapy milestone, studying young-onset cancers, and more
This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the…
STAT+: Pharmalittle: We’re reading about an AstraZeneca bladder cancer drug, Genentech anxiety, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
The essential biotech updates of the day
Morning! Today, we talk about bioethics, catch up on some reports from ESMO, and wonder aloud…
Pediatricians’ obesity guidelines rest on shaky evidence about eating disorder risks
To address soaring rates of childhood obesity, the American Academy of Pediatrics last year endorsed…
News from ESMO: An AstraZeneca win in bladder cancer, and more
This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the…
STAT+: BMS immunotherapy boosts responses in lung cancer, setting up Phase 3 study
BARCELONA, Spain — Adding a second immunotherapy from Bristol Myers Squibb to an existing checkpoint…
The news from ESMO: The latest on anti-TIGIT data, a PD-(L)1 injection, and more
This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the…
STAT+: FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug
Swiss pharma giant Roche won approval from the Food and Drug Administration on Friday for…
Can GLP-1 drugs help with type 1 diabetes?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
FDA is taking on tampons and ‘misleading’ ads starring Serena Williams
Good morning! I’ve decided today is the day that I must tell you about my…
Moderna cuts spending, and Sarepta’s ‘curse’ on Califf
Good morning. If you’re following the European Society for Medical Oncology meeting that starts tomorrow,…
STAT+: ‘Sarepta’s like a curse on me’: FDA commissioner dismisses controversy over approval
WELLESLEY, Mass. — At an event with journalists Tuesday outside of Boston, U.S. Food and…
Eli Lilly releases new data on weekly insulin
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Five biotech news stories you need to read today
Morning! Today, we’ll keep riding the bispecific wave, and tell you what Verily and FDA…
The little-known bill that made drugs more affordable
This is Part 4 of “Behind the Counter,” an in-depth video series demystifying the complex…
With TV drug ads, what you see is not necessarily what you get
Triumphant music plays as cancer patients go camping, do some gardening, and watch fireworks in ads…
Terns’ GLP-1 pill leads to weight loss in early study
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: With a win in lung cancer, biotech’s wealthiest outsider surfs to new heights
On Sunday, a small biotech company called Summit Therapeutics won a remarkable victory, saying its…
Opinion: How Pfizer ended up passing on my GLP-1 work back in the early ’90s
One of the biopharma industry’s marvels of the 2020s has been the enormous medical and…
STAT+: Pharmalittle: We’re reading about FDA inspections, Lilly insulin trial results, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: U.K. charities give $36 million to start new drugs for childhood tumors
For three decades, adults have benefited from a revolution in oncology treatment, as immunotherapies and…
Nearly 2,000 drug manufacturing plants are overdue for FDA inspections after Covid delays
Federal regulators responsible for the safety of the U.S. drug supply are still struggling to…
Lilly has more positive data on its weekly insulin
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about China detaining AstraZeneca staff, pharma layoffs, and more
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target
Nearly two decades ago, a small company called Amylin Pharmaceuticals saw that its first commercial…
.jpg)
STAT+: Pharmalittle: We’re reading about a Vaxcyte vaccine, Ozempic shortages, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
BioMarin’s big day today
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Medicare drug prices, a Sanofi MS pill, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT+: At major cardiology conference, Wegovy’s the word
LONDON — When Europe’s largest cardiology conference opened here this past Friday, one of the…
STAT+: Sanofi says its new pill for multiple sclerosis succeeded in a key trial, boosting its research ambitions
Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a…
STAT+: Pharmalittle: We’re reading about Wegovy study results, an Alnylam heart drug, and more
And so, another working week will soon draw to a close. Not a moment too…
Switching asthma inhalers could reduce carbon emissions, says study
Concerns over health care’s carbon footprint typically revolve around issues like overly-air-conditioned hospitals and single-use…
STAT+: Pharmalittle: We’re reading about Zepbound pricing caveats, PBM congressional testimony, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
Genentech is shedding even more employees
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Zantac court cases, a Neurocrine schizophrenia pill, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
Hims takes a blow from Lilly’s vial news
Good morning. As a treat for Labor Day weekend, we’re running a deal for STAT+…
STAT+: Pharmalittle: We’re reading about Lilly cutting Zepbound’s price; Pfizer selling direct to consumers, and more
Good morning, everyone, and how are you today? We are just fine, thank you, especially…
Pfizer and Lilly want to sell you drugs directly
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: To help migraine patients — and sell more medicines — major drugmakers turn to telehealth
In 2021, Katey Frederking had reached the end of her rope. The 29-year-old was struggling…
A Galapagos investor signals impatience with its turnaround efforts
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: UCB selling a Chinese business, Tome layoffs, and more
Happy Monday, Pharmalittle family. Adam Feuerstein here, once again filling in for Ed. I have…
STAT+: Pharmalittle: We’re reading about AstraZeneca threatening the U.K., mpox vaccine distribution, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about a negative U.K. review of Leqembi, Bavarian Nordic’s strong earnings, and more
Good morning, Pharmalittle fans! Adam Feuerstein here, filling in for Ed. I drink my morning…
STAT+: Pharmalittle: We’re reading about obesity drugs and suicidal thoughts, a FDA official’s conflicts, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…